Mrs Allison Steigler

Statistician

School of Medicine and Public Health

Career Summary

Biography

Research Expertise
Since 2003 I have the trial coordinator of the TROG 96.01 prostate cancer trial.

Qualifications

  • Bachelor of Mathematics, University of Newcastle

Keywords

  • clinical trials
  • prostate cancer

Fields of Research

Code Description Percentage
029999 Physical Sciences not elsewhere classified 50
110399 Clinical Sciences not elsewhere classified 25
111299 Oncology and Carcinogenesis not elsewhere classified 25
Edit

Publications

For publications that are currently unpublished or in-press, details are shown in italics.


Journal article (32 outputs)

Year Citation Altmetrics Link
2015 Denham JW, Steigler A, Joseph D, Lamb DS, Spry NA, Duchesne G, et al., 'Radiation dose escalation or longer androgen suppression for locally advanced prostate cancer? Data from the TROG 03.04 RADAR trial.', Radiother Oncol, 115 301-307 (2015)
DOI 10.1016/j.radonc.2015.05.016
Co-authors Christopher Oldmeadow, Liz Holliday, John Attia
2014 Denham JW, Nowitz M, Joseph D, Duchesne G, Spry NA, Lamb DS, et al., 'Impact of androgen suppression and zoledronic acid on bone mineral density and fractures in the Trans-Tasman Radiation Oncology Group (TROG) 03.04 Randomised Androgen Deprivation and Radiotherapy (RADAR) randomized controlled trial for locally advanced prostate cancer', BJU International, 114 344-353 (2014) [C1]

Objective To study the influence of adjuvant androgen suppression and bisphosphonates on incident vertebral and non-spinal fracture rates and bone mineral density (BMD) in men wit... [more]

Objective To study the influence of adjuvant androgen suppression and bisphosphonates on incident vertebral and non-spinal fracture rates and bone mineral density (BMD) in men with locally advanced prostate cancer. Patients and Methods Between 2003 and 2007, 1071 men with locally advanced prostate cancer were randomly allocated, using a 2 × 2 trial design, to 6 months i.m. leuprorelin (androgen suppression [AS]) before radiotherapy alone ± 12 months additional leuprorelin ± 18 months zoledronic acid (ZdA), commencing at randomization. The main endpoint was incident thoraco-lumbar vertebral fractures, which were assessed radiographically at randomization and at 3 years, then reassessed by centralized review. Subsidiary endpoints included incident non-spinal fractures, which were documented throughout follow-up, and BMD, which was measured in 222 subjects at baseline, 2 years and 4 years. Results Incident vertebral fractures at 3 years were observed in 132 subjects. Their occurrence was not increased by 18 months' AS, nor reduced by ZdA. Incident non-spinal fractures occurred in 72 subjects and were significantly related to AS duration but not to ZdA. Osteopenia and osteoporosis prevalence rates at baseline were 23.4 and 1.4%, respectively, at the hip. Treatment for 6 and 18 months with AS caused significant reductions in hip BMD at 2 and 4 years (P < 0.01) and ZdA prevented these losses at both time points. Conclusion In an AS-naïve population, 18 months of ZdA treatment prevented the sustained BMD losses caused by 18 months of AS treatment; however, the study power was insufficient to show that AS duration or ZdA influenced vertebral fracture rates. © 2013 The Authors. BJU International © 2013 BJU International.

DOI 10.1111/bju.12497
Citations Scopus - 4Web of Science - 7
Co-authors Catherine Deste, Pablo Moscato, Patrick Mcelduff
2014 Denham JW, Nowitz M, Joseph D, Duchesne G, Spry NA, Lamb DS, et al., 'Impact of androgen suppression and zoledronic acid on bone mineral density and fractures in the Trans-Tasman Radiation Oncology Group (TROG) 03.04 Randomised Androgen Deprivation and Radiotherapy (RADAR) randomized controlled trial for locally advanced prostate cancer', BJU International, 114 344-353 (2014) [C1]

Objective To study the influence of adjuvant androgen suppression and bisphosphonates on incident vertebral and non-spinal fracture rates and bone mineral density (BMD) in men wit... [more]

Objective To study the influence of adjuvant androgen suppression and bisphosphonates on incident vertebral and non-spinal fracture rates and bone mineral density (BMD) in men with locally advanced prostate cancer. Patients and Methods Between 2003 and 2007, 1071 men with locally advanced prostate cancer were randomly allocated, using a 2 × 2 trial design, to 6 months i.m. leuprorelin (androgen suppression [AS]) before radiotherapy alone ± 12 months additional leuprorelin ± 18 months zoledronic acid (ZdA), commencing at randomization. The main endpoint was incident thoraco-lumbar vertebral fractures, which were assessed radiographically at randomization and at 3 years, then reassessed by centralized review. Subsidiary endpoints included incident non-spinal fractures, which were documented throughout follow-up, and BMD, which was measured in 222 subjects at baseline, 2 years and 4 years. Results Incident vertebral fractures at 3 years were observed in 132 subjects. Their occurrence was not increased by 18 months' AS, nor reduced by ZdA. Incident non-spinal fractures occurred in 72 subjects and were significantly related to AS duration but not to ZdA. Osteopenia and osteoporosis prevalence rates at baseline were 23.4 and 1.4%, respectively, at the hip. Treatment for 6 and 18 months with AS caused significant reductions in hip BMD at 2 and 4 years (P < 0.01) and ZdA prevented these losses at both time points. Conclusion In an AS-naïve population, 18 months of ZdA treatment prevented the sustained BMD losses caused by 18 months of AS treatment; however, the study power was insufficient to show that AS duration or ZdA influenced vertebral fracture rates. © 2013 The Authors. BJU International © 2013 BJU International.

DOI 10.1111/bju.12497
Citations Scopus - 2
Co-authors Patrick Mcelduff, Pablo Moscato, Catherine Deste
2014 Denham JW, Joseph D, Lamb DS, Spry NA, Duchesne G, Matthews J, et al., 'Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial', LANCET ONCOLOGY, 15 1076-1089 (2014) [C1]
DOI 10.1016/S1470-2045(14)70328-6
Citations Scopus - 3Web of Science - 3
Co-authors Christopher Oldmeadow, John Attia
2014 Denham JW, Nowitz M, Joseph D, Duchesne G, Spry NA, Lamb DS, et al., 'Impact of androgen suppression and zoledronic acid on bone mineral density and fractures in the Trans-Tasman Radiation Oncology Group (TROG) 03.04 Randomised Androgen Deprivation and Radiotherapy (RADAR) randomized controlled trial for locally advanced prostate cancer.', BJU Int, 114 344-353 (2014) [C1]
DOI 10.1111/bju.12497
Citations Web of Science - 6
Co-authors Catherine Deste, Patrick Mcelduff, Pablo Moscato
2013 Denham JW, Steigler A, Tai K, Joseph D, Matthews J, Atkinson C, et al., 'Paradoxical metastatic progression following 3 months of neo-adjuvant androgen suppression in the TROG 96.01 trial for men with locally advanced prostate cancer', Radiotherapy and Oncology, 107 123-128 (2013) [C1]
DOI 10.1016/j.radonc.2013.03.025
Citations Scopus - 2Web of Science - 1
2013 Denham JW, Steigler A, 'Picking the Optimal Duration of Hormonal Therapy in Men With High-Risk and Locally Advanced Prostate Cancer Treated With Radiotherapy', Seminars in Radiation Oncology, 23 206-214 (2013) [C1]
DOI 10.1016/j.semradonc.2013.01.008
Citations Scopus - 2
2012 Wilcox C, Kautto AJ, Steigler A, Denham J, 'Androgen deprivation therapy for prostate cancer does not increase cardiovascular mortality in the long term', Oncology: International Journal of Cancer Research and Treatment, 82 56-58 (2012) [C1]
Citations Scopus - 6Web of Science - 7
2012 D'Amico AV, Chen M-H, De Castro M, De Castro M, Lamb DS, Steigler A, et al., 'Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: An analysis of two randomised trials', Lancet Oncology, 13 189-195 (2012) [C1]
Citations Scopus - 16Web of Science - 14
2012 Steigler A, Denham J, Lamb DS, Spry NA, Joseph D, Matthews J, et al., 'Risk stratification after biochemical failure following curative treatment of locally advanced prostate cancer: Data from the TROG 96.01 trial', Prostate Cancer, 2012 1-11 (2012) [C1]
2011 Ebert MA, Lamb DS, Joseph DJ, Steigler A, Denham J, 'A methodology for the analysis of PSA response signatures', Radiotherapy and Oncology, 98 198-202 (2011) [C1]
DOI 10.1016/j.radonc.2010.11.013
Citations Scopus - 1
2011 Denham J, Lamb DS, Joseph D, Matthews J, Atkinson C, Spry NA, et al., 'Another form of subgroup to beware', Radiotherapy and Oncology, 101 525-526 (2011) [C3]
DOI 10.1016/j.radonc.2011.08.032
Citations Scopus - 1Web of Science - 1
Co-authors Catherine Deste
2011 Lamb DS, Denham J, Joseph D, Matthews J, Atkinson C, Spry NA, et al., 'A comparison of the prognostic value of early PSA test-based variables following external beam radiotherapy, with or without preceding androgen deprivation: Analysis of data from the TROG 96.01 randomized trial', International Journal of Radiation Oncology Biology Physics, 79 385-391 (2011) [C1]
DOI 10.1016/j.ijrobp.2009.10.071
Citations Scopus - 15Web of Science - 13
Co-authors Catherine Deste
2011 D'Amico AV, Chen MH, Crook J, Armstrong JG, Malone S, Steigler A, et al., 'Duration of short-course androgen suppression therapy and the risk of death as a result of prostate cancer', Journal of Clinical Oncology, 29 4682-4687 (2011) [C1]
DOI 10.1200/jco.2011.37.0726
Citations Scopus - 5Web of Science - 5
2011 Denham J, Steigler A, Lamb DS, Joseph D, Turner S, Matthews J, et al., 'Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial', The Lancet Oncology, 12 451-459 (2011) [C1]
DOI 10.1016/s1470-2045(11)70063-8
Citations Scopus - 115Web of Science - 102
Co-authors Catherine Deste
2010 Kumar M, Denham J, Steigler A, 'Value of combined androgen blockade in the neoadjuvant treatment of localized prostate cancer: The jury must remain out', Journal of Clinical Oncology, 28 E445-E446 (2010) [C3]
DOI 10.1200/JCO.2010.29.4868
Citations Scopus - 1Web of Science - 1
2009 Denham J, Steigler A, Wilcox C, Lamb DS, Joseph D, Atkinson C, et al., 'Why are pretreatment prostate-specific antigen levels and biochemical recurrence poor predictors of prostate cancer survival?', Cancer, 115 4477-4487 (2009) [C1]
DOI 10.1002/cncr.24484
Citations Scopus - 18Web of Science - 17
Co-authors Catherine Deste
2009 Denham J, Lamb DS, Joseph D, Matthews J, Atkinson C, Spry NA, et al., 'PSA response signatures: A powerful new prognostic indicator after radiation for prostate cancer?', Radiotherapy and Oncology, 90 382-388 (2009) [C1]
DOI 10.1016/j.radonc.2008.10.004
Citations Scopus - 11Web of Science - 11
Co-authors Catherine Deste
2009 Capp A, Inostroza-Ponta M, Bill D, Moscato PA, Lai C, Christie D, et al., 'Is there more than one proctitis syndrome? A revisitation using data from the TROG 96.01 trial', Radiotherapy and Oncology, 90 400-407 (2009) [C1]
DOI 10.1016/j.radonc.2008.09.019
Citations Scopus - 40Web of Science - 36
Co-authors Pablo Moscato
2009 Denham J, Kumar M, Gleeson PS, Lamb DS, Joseph D, Atkinson C, et al., 'Recognizing false biochemical failure calls after radiation with or without neo-adjuvant androgen deprivation for prostate cancer', International Journal of Radiation Oncology Biology Physics, 74 404-411 (2009) [C1]
DOI 10.1016/j.ijrobp.2008.08.047
Citations Scopus - 7Web of Science - 6
Co-authors Catherine Deste, Peter Greer
2009 Denham J, Steigler A, Kumar M, Lamb DS, Joseph D, Spry NA, et al., 'Measuring time to biochemical failure in the Trog 96.01 trial: When should the clock start ticking?', International Journal of Radiation Oncology Biology Physics, 75 1008-1012 (2009) [C1]
DOI 10.1016/j.ijrobp.2008.12.085
Citations Scopus - 4Web of Science - 3
Co-authors Catherine Deste, Peter Greer
2008 Denham J, Steigler A, Wilcox C, Lamb DS, Joseph D, Atkinson C, et al., 'Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial', Lancet Oncology, 9 1058-1068 (2008) [C1]
DOI 10.1016/s1470-2045(08)70236-5
Citations Scopus - 41Web of Science - 36
Co-authors Peter Greer, Catherine Deste
2007 D'Amico AV, Denham J, Crook J, Chen MH, Goldhaber SZ, Lamb DS, et al., 'Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions', Journal of Clinical Oncology, 25 2420-2425 (2007) [C1]
DOI 10.1200/JCO.2006.09.3369
Citations Web of Science - 270
2007 D'Amico AV, Denham J, Bolla M, Collette L, Lamb DS, Tai KH, et al., 'Short- vs long-term androgen suppression plus external beam radiation therapy and survival in men of advanced age with node-negative high-risk adenocarcinoma of the prostate', Cancer, 109 2004-2010 (2007) [C1]
DOI 10.1002/cncr.22628
Citations Scopus - 23Web of Science - 20
2005 Christie D, Denham J, Steigler A, Lamb D, Turner S, Mameghan H, et al., 'Delayed rectal and urinary symptomatology in patients treated for prostate cancer by radiotherapy with or without short term neo-adjuvant androgen deprivation', Radiotherapy and oncology, 77 117-125 (2005) [C1]
DOI 10.1016/j.radonc.2005.10.005
Citations Scopus - 38Web of Science - 33
Co-authors Catherine Deste
2005 Danham JW, Steigler A, Lamb DS, Joseph D, Turner S, Matthews J, et al., 'TROG 96.01: first report of the main endpoints', EJC SUPPLEMENTS, 3 230-231 (2005)
2005 Denham J, Steigler A, Lamb D, Joseph D, Mameghan H, Turner S, et al., 'Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer : results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial', The Lancet, 6 841-850 (2005) [C1]
DOI 10.1016/S1470-2045(05)70348-X
Citations Scopus - 271Web of Science - 236
Co-authors Catherine Deste
2005 Back M, Ahern V, Delaney G, Graham P, Steigler A, Wratten C, 'Absence of adverse early quality of life outcomes of radiation therapy in breast conservation therapy for early breast cancer', Journal of Medical Imaging and Radiation Oncology, 49 39-43 (2005) [C1]
DOI 10.1111/j.1440-1673.2005.01392.x
Citations Scopus - 16
2004 Back M, Guerrieri M, Wratten C, Steigler A, 'Impact of radiation therapy on acute toxicity in breast conservation therapy for early breast cancer', CLINICAL ONCOLOGY, 16 12-16 (2004)
DOI 10.1016/j.clon.2003.08.005
Citations Scopus - 41Web of Science - 32
2003 Denham J, Steigler A, Kilmurray J, Wratten C, Burmeister B, Lam D, et al., 'Relapse patterns after chemo-radiation for carcinoma of the oesophagus', Clinical Oncology, 15 98-108 (2003) [C1]
DOI 10.1053/clon.2003.0212
Citations Scopus - 35Web of Science - 31
Co-authors Stephen Ackland
2000 Steigler A, Mameghan H, Lamb D, Joseph D, Matthews J, Franklin I, et al., 'A quality assurance audit: Phase 111 trial of maximal androgen deprivation in prostate cancer (TROG 96.01)', AUSTRALASIAN RADIOLOGY, 44 65-71 (2000) [C1]
Citations Scopus - 11
1999 Hamilton C, Poulsen M, Walker Q, Krawitz H, Hindley A, Spry N, et al., 'Quality assurance audit in an Australasian phase III trial of accelerated radiotherapy for head and neck cancer (TROG 91.01). Trans-Tasman Radiation Oncology Group.', Australasian radiology, 43 227-232 (1999)
DOI 10.1046/j.1440-1673.1999.00639.x
Show 29 more journal articles

Conference (9 outputs)

Year Citation Altmetrics Link
2015 Warren LE, Chen M-H, Denham JW, Steigler A, Renshaw AA, Loffredo MJ, et al., 'Gleason grade 5 and the risk of death from prostate cancer following radiation with or without 6 months of conventional androgen deprivation therapy.', JOURNAL OF CLINICAL ONCOLOGY, Chicago, IL (2015)
2011 Denham J, Steigler A, Lamb DS, Joseph DJ, Matthews J, Atkinson C, et al., 'Variations in androgen dependent clinical progression kinetics in locally advanced prostate cancer', European Journal of Cancer, Stockholm, Sweden (2011) [E3]
Co-authors Catherine Deste
2007 Denham J, Joseph D, Lamb D, Tai KH, Turner S, Matthews J, et al., 'Reasons for initial PSA (iPSA) and biochemical failure (BF) being poor predictors of prostate cancer (PC) mortality', European Journal of Cancer Supplements (ECCO 14 Abstract Book), Barcelona, Spain (2007) [E3]
DOI 10.1016/s1359-6349(07)71071-6
Co-authors Peter Greer
2006 Joseph D, Lamb D, Denham J, Tai K-H, Turner S, Matthews J, et al., 'The biological significance of longitudinal changes in PSA; Post treatment variation sand mistaken biochemical failure.', RADIOTHERAPY AND ONCOLOGY, Leipzig, GERMANY (2006)
Co-authors Peter Greer
2006 Denham J, Joseph D, Lamb D, Tai K-H, Turner S, Matthews J, et al., 'The biological significance of longitudinal changes in PSA; Doubling time during biochemical failure', RADIOTHERAPY AND ONCOLOGY, Leipzig, GERMANY (2006)
Co-authors Peter Greer
2006 Lamb D, Denham J, Joseph D, Tai K, Turner S, Matthews J, et al., 'The biological significance of longitudinal changes in PSA; Post treatment variations and mistaken biochemical failure', INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, Philadelphia, PA (2006)
DOI 10.1016/j.ijrobp.2006.07.632
Co-authors Peter Greer
2006 Lamb D, Denham J, Joseph D, Tai K, Turner S, Matthews J, et al., 'The biological significance of longitudinal changes in PSA: Post treatment variations and mistaken biochemical failure', Proceedings of the 48th Annual Meeting of the American Society for Therapeutic Radiology and Oncology, 48th Annual Meeting of the American Society for Therapeutic Radiology and Oncology, Philadelphia, PA (2006) [E3]
2006 Denham J, Joseph D, Lamb D, Tai K, Turner S, Matthews J, et al., 'The biological significance of longitudinal changes in PSA; Doubling time during biochemical failure', Proceedings of the 48th Annual Meeting of the American Society for Therapeutic Radiology and Oncology, 48th Annual Meeting of the American Society for Therapeutic Radiology and Oncology, Philadelphia, PA (2006) [E3]
Co-authors Peter Greer
2006 Joseph D, Denham J, Lamb D, Tai K, Turner S, Matthews J, et al., 'The biological significance of longitudinal changes in PSA; PSA response signatures (PRS)', Proceedings of the 48th Annual Meeting of the American Society for Therapeutic Radiology and Oncology, 48th Annual Meeting of the American Society for Therapeutic Radiology and Oncology, Philadelphia, PA (2006) [E3]
Show 6 more conferences
Edit

Grants and Funding

Summary

Number of grants 1
Total funding $399,565

Click on a grant title below to expand the full details for that specific grant.


20071 grants / $399,565

Optimal duration of neoadjuvant androgen deprivation therapy in localised prostate cancer$399,565

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Conjoint Professor Jim Denham, Mrs Allison Steigler
Scheme Project Grant
Role Investigator
Funding Start 2007
Funding Finish 2007
GNo G0186389
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y
Edit

Mrs Allison Steigler

Position

Statistician
Prostate Cancer Clinical Trials Group
School of Medicine and Public Health
Faculty of Health and Medicine

Contact Details

Email allison.steigler@newcastle.edu.au
Phone (02) 4985 4019
Fax (02) 4968 4924

Office

Room WTPO 118
Building Waratah Post Office
Location Other

,
Edit